Last reviewed · How we verify
Icotinib with concurrent radiotherapy
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor Used for Non-small cell lung cancer.
At a glance
| Generic name | Icotinib with concurrent radiotherapy |
|---|---|
| Also known as | Icotinib, Comana, BPI-2009 |
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Drug class | EGFR tyrosine kinase inhibitor |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Icotinib is a small molecule inhibitor that targets the epidermal growth factor receptor (EGFR) tyrosine kinase, thereby inhibiting the proliferation of cancer cells.
Approved indications
- Non-small cell lung cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation (PHASE2)
- EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC (PHASE3)
- IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer (NA)
- Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer (PHASE3)
- First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation (PHASE3)
- A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy (PHASE2)
- RT Plus EGFR-TKI for Wild-type NSCLC (PHASE2)
- Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |